NCT07445893

A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV

A Clinical Study of Gecacitinib Hydrochloride Tablets Combined With Pegylated Interferon as First-line Treatment in Patients With Polycythemia Vera (PV)

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Duan Minghui · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of Gecacitinib in combination with pegylated interferon for the treatment of polycythemia vera (PV).The main question it aims to answer is: Can PV patients achieve hematological remission after receiving the combination therapy? Participants will: Receive combination treatment with Gecacitinib Hydrochloride Tablets and pegylated interferon for 24 weeks Visit the hospital regularly for examinations and follow-up assessments

Conditions

• Polycythemia Vera (PV)

Interventions

Type	Name	Description
DRUG	Gecacitinib Hydrochloride Tablets；Pegylated interferon alfa-2b	Gecacitinib Hydrochloride Tablets: 100 mg twice daily (BID), orally, on an empty stomach. Pegylated interferon alfa-2b: 90 μg once weekly, subcutaneous injection in the abdomen or thigh.

Timeline

• Start date: 2026-02-24
• Primary completion: 2026-12-30
• Completion: 2028-12-30
• First posted: 2026-03-03
• Last updated: 2026-03-03